InvestorWire NewsRoom


InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Presents Data Regarding Drug Candidate for Replacement of Addictive Benzodiazepines
March 22, 2021

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Presents Data Regarding Drug Candidate for Replacement of Addictive Benzodiazepines

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new-generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, presented data highlighting the proposed mechanism of action (“MOA”) of its Phase 3 investigational drug candidate, PH94B nasal spray, in a poster session at the Anxiety and Depression Association of America’s 2021 Virtual Annual Conference. VTGN’s PH94B spray is designed to provide rapid-onset acute treatment of anxiety without directly activating gamma-amino butyric acid (“GABA-A”) receptors. This approach differentiates PH94B from benzodiazepines such as alprazolam, diazepam and lorazepam, which are direct GABA-A receptor positive modulators. The objective is for PH94B to displace these and other benzodiazepines, which are widely used but addictive, as a viable treatment for social anxiety disorder (“SAD”) and other anxiety disorders and phobias. SAD is the third most common mental health disorder among Americans, and recent studies indicate that an estimated 20 million individuals suffer with the debilitating disorder. “Given the FDA’s recent Drug Safety Communication that outlined and highlighted the safety risks associated with benzodiazepine use, the implications resulting from this study are significant,” said VistaGen chief medical officer Mark Smith, M.D., Ph.D., in the press release. “PH94B may have the potential to displace benzodiazepines altogether and become the safer alternative to help the millions of Americans suffering from anxiety with limited options for safe, effective treatment options. These existing treatments can actually hurt instead of help. We look forward to launching our Phase 3 clinical development program for PH94B next quarter and continuing to push forward in our mission to get it into the hands of those in need as soon as possible.”

To view the full press release, visit

About VistaGen Therapeutics Inc.

VistaGen is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated potential mechanism of action, has been well tolerated in all clinical studies to date and has therapeutic potential in multiple CNS markets. For more information about the company, please visit

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).